← All trials
NCT05329090
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 11, 2022
- Primary completion
- Mar 11, 2025
- Completion date
- Mar 11, 2026
- First posted
- Apr 14, 2022
- Last posted
- Apr 14, 2022
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of VersaillesLead sponsor
- Government of FranceCollaborator
- Hôpital FOCHOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.